March 2026—Blood-based biomarkers for Alzheimer’s disease, including the FDA-approved Lumipulse G pTau 217/β-Amyloid 1-42 and Elecsys pTau181 tests, are revolutionizing diagnosis and treatment. These less invasive tests offer earlier detection, improved accessibility, and potential for broader patient reach.
March 2026—An international panel of experts recommended including the determination of intrathecal kappa free light chain (κ-FLC) synthesis in the next revision of MS diagnostic criteria. The κ-FLC index, easily determined by nephelometry and turbidimetry, is a fast, cost-effective, and quantitative biomarker with high diagnostic value for MS. It also predicts future inflammatory disease activity and disability progression, making it a valuable prognostic tool.
SPONSORED ROUNDTABLES
February 2026—This is the fourth in a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with representatives of a company to spotlight its laboratory solutions. He spoke on Dec. 2, 2025 with Steve Swartzell and Scott Johnston of ELITechGroup.
CAP TODAY RECOMMENDS
February 2026—Prepared with expert insight from Anil Parwani, MD, PhD; Scott Hammond; and Melinda Schumacher, MD, Grundium’s white paper describes, from a pathologist’s perspective, how compact WSI systems can shorten consult turnaround times and reduce variability, improve access to subspecialty review without adding travel or courier burden, enhance community pathologists’ professional satisfaction and confidence, support scalable, secure, and validated workflows and lay the foundation for AI and advanced analytics as digital adoption grows. Download the white paper here.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: URINALYSIS
March 2026—A roundtable discussion focused on improving workflow efficiency in urinalysis, highlighting the potential of AI to enhance reflex testing by integrating test results with EHR data.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
November 2024—Randox now offers Olink dual-antibody recognition and proximity extension assay (PEA) technology, bringing the Olink Explore, Target, and Flex panels in-house to accelerate highly specific multiplex biomarker screening.